Skip to Content
Søk Menu

Vaccinating Against Mutated RAS in Multiple Myeloma

At EHA 2024, Hanne Norseth, MD, PhD student, Oslo Myeloma Center, Norway, presents a study that aims to evaluate vaccinating against mutated RAS in multiple myeloma. In this MEDtalk, Hanne Norseth presents the tentative data of the ongoing study.
Hanne Norseth

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

The Aquila Study Strongly Supports the Benefit of Early Intervention with Daratumumab Monotherapy in Patients with High-Risk Smoldering Multiple Myeloma

/ Jan Andreasen
ASH24Myelomatose
Fredrik Schjesvold

Det Trispesifikke Antistoffet SAR’257 Avviklet Etter Fase 1-Funn

/ Fredrik Schjesvold
ASH24Myelomatose Play the Video 03:49

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ BestPractice Nordic
EHA24Myelomatose

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymfom

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
CLLEHA24

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24
Fredrik Schjesvold

Fredrik Schjesvold: Mine erfaringer med å bygge Myeloma Center (Oslo Myelomatosesenter)

/ Fredrik Schjesvold
MyelomatoseOnkologisk Forum 2024 Play the Video 03:20

Using PRO Data to Assess Treatment Readiness in Multiple Myeloma

/ Tine Rosenberg / Thomas Lund / Jannie Kirkegaard
Myelomatose

New Data from EHA Shared and Discussed at Danish Evening

/ Jan Andreasen
EHA24
Back to top